Simon C, Plinkert P K
HNO-Universitätsklinik Heidelberg, Im Neuenheimer Feld 400, 69120, Heidelberg.
HNO. 2008 Jun;56(6):575-84. doi: 10.1007/s00106-008-1718-x.
The survival rate in patients with head and neck squamous cell cancer (HNSCC) has improved considerably over the past 50 years. This is due not only to changes in anesthetic techniques, but also to the fact that combinations of various therapeutic approaches are more common than they used to be. It is generally accepted that patients with advanced carcinomas require combined modality treatment. It has yet to be established which modality is best to use as the primary treatment. Approaches that begin with radiotherapy or chemotherapy were the most commonly used for a while, but indications are now increasingly being seen that primary surgery leads to good results. Moreover, the use of the epidermal growth factor (EGF) antibody cetuximab has recently been playing an increasingly important role.
在过去50年里，头颈部鳞状细胞癌（HNSCC）患者的生存率有了显著提高。这不仅归因于麻醉技术的变革，还得益于多种治疗方法联合使用比过去更为普遍这一事实。人们普遍认为，晚期癌症患者需要综合治疗。然而，哪种治疗方式最适合作为主要治疗手段仍有待确定。一段时间以来，以放疗或化疗开始的治疗方法最为常用，但现在越来越多的迹象表明，初次手术能带来良好的效果。此外，表皮生长因子（EGF）抗体西妥昔单抗的应用近来也发挥着越来越重要的作用。
